Takeda ProThera Collaboration, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha]
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) (TAK)
Company Research
Source: Seeking Alpha
SummaryTakeda teams up with ProThera to develop therapies for acute inflammatory conditions.Gilead slumps on leaked document showing remdesivir failure.Daxor jumps on DoD contract.Takeda Teams Up with ProThera on IAIP TherapyTakeda Pharmaceutical Company Limited (TAKThe global licensing deals with IAIP which is a naturally occurring protein circulating in the blood. The research conducted by ProThera shows that such proteins may aid the process of controlling inflammation. Denice Spero, president and chief business officer of ProTherasaidTakeda is consistently working towards boosting its portfolio of plasma derived therapies. The company had made a foray in this direction with its acquisition of Shire, which came with a price tag of nearly $62 billion. However, the company has notdisclosedThis development underscores Takeda’s attempt to take its business in a new direction. The company recently announced its deal with Oriflame. Under this $670 million agreement, Takeda will dispose o
Show less
Read more
Impact Snapshot
Event Time:
TAK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TAK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TAK alerts
High impacting Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) news events
Weekly update
A roundup of the hottest topics
TAK
News
- Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform [Yahoo! Finance]Yahoo! Finance
- Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy PlatformBusiness Wire
- Latigo Biotherapeutics Appoints Industry Veteran Timothy P. Walbert as Board Chair [Yahoo! Finance]Yahoo! Finance
- New Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD [Yahoo! Finance]Yahoo! Finance
- Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook [Yahoo! Finance]Yahoo! Finance
TAK
Sec Filings
- 10/31/24 - Form 6-K
- 10/31/24 - Form 6-K
- 10/31/24 - Form 6-K
- TAK's page on the SEC website